Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR84 | Q9NQS5 | 2/20 | 0.32 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.31 |
| ▸ | OPRM1 | P35372 | 3/20 | 0.31 |
| ▸ | OPRK1 | P41145 | 3/20 | 0.31 |
| ▸ | OPRD1 | P41143 | 2/20 | 0.31 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.31 |
| ▸ | AR | P10275 | 1/20 | 0.31 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.31 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.31 |
| ▸ | HTR2A | P28223 | 1/20 | 0.31 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.31 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.31 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.31 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.31 |
| ▸ | SCN5A | Q14524 | 1/20 | 0.31 |
| ▸ | GRIN2B | Q13224 | 2/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7946133 | 0.79 | MGLL (0.36) | OPRM1OPRK1OPRD1 | |
| SCHEMBL5072194 | 0.74 | PTGER2 (0.39) | — | |
| SCHEMBL11711459 | 0.73 | FAAH (0.33) | — | |
| SCHEMBL11711444 | 0.73 | PTGER2 (0.41) | — | |
| SCHEMBL7886844 | 0.73 | PTGER2 (0.41) | — | |
| SCHEMBL11711753 | 0.70 | PTGER4 (0.31) | — | |
| SCHEMBL11711762 | 0.67 | PTGER4 (0.50) | — | |
| SCHEMBL11712446 | 0.66 | PTGER1 (0.37) | — | |
| SCHEMBL11719171 | 0.66 | PTGER1 (0.37) | — | |
| SCHEMBL7819517 | 0.64 | DAO (0.50) | HTR2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7255984-B2 | Combination therapy for osteoporosis | PFIZER INC. (US) | 2007-08-14 | — | — | US | disclosed |
| US-20010009920-A1 | Estrogen agonist/antagonist and a prostaglandin or a prostaglandin agonist/antagonist | KE HUA ZHU (US) | 2001-07-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20010009920-A1 | Estrogen agonist/antagonist and a prostaglandin or a prostaglandin agonist/antagonist | PTGER1, PTGER2, PTGER4 | GPR84 100/4885TRPV1 468/4885OPRM1 146/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.